Advertisement
For men with non-metastatic castration-resistant prostate cancer

Apalutamide Active in Castration-Resistant Prostate Cancer

0
Apalutamide prolongs metastasis-free survival in non-metastatic castration-resistant prostate cancer
Care quality for patients with transient ischemic attack or minor stroke varies substantially across elements of care and facilities

Marked Variation Seen in Care Quality for TIA, Minor Stroke

0
Room for improvements in care, particularly for patients treated only in emergency departments
Compliance with guideline-directed medical therapy is low

Guideline-Directed Medical Tx Adherence Low Post CABG

0
Compliance higher in PCI than CABG, but remains low in contemporary clinical trials
Patient

Patient, Provider Characteristics Tied to Unnecessary Antibiotic Rx

0
Advanced practice practitioners may be more likely to prescribe unnecessary antibiotics
For patients with severe hereditary hemorrhagic telangiectasia-related bleeding

IV Bevacizumab Effective for Severe HHT-Related Bleeding

0
Drop in RBC transfusion requirements, epistaxis severity in hereditary hemorrhagic telangiectasia
For patients with diabetic macular edema

Persistent DME More Likely With Bevacizumab Treatment

0
Persistent diabetic macular edema more likely with bevacizumab than aflibercept or ranibizumab
Exposure to ibuprofen is harmful to developing human fetal ovaries ex vivo in the first trimester

Ibuprofen May Harm Fetal Ovaries During First Trimester

0
Pregnant women who take ibuprofen in the first trimester may reduce daughters' egg reserve

January 2018 Briefing – Pharmacy

0
Here are what the editors at HealthDay consider to be the most important developments in Pharmacy for January 2018. This roundup includes the latest...
The number of users who exceed the daily limit of nonsteroidal anti-inflammatory drugs is "nontrivial

NSAID Users Commonly Exceed Daily Limit

0
Educating consumers about dosing directions could improve dosing compliance
Once-daily treatment with glecaprevir-pibrentasvir appears safe and effective for the treatment of hepatitis C virus genotype 1 or 3

Glecaprevir-Pibrentasvir Effective Treatment for HCV Genotypes 1, 3

0
Once-daily treatment for eight or 12 weeks yields high rates of sustained virologic response